<DOC>
	<DOCNO>NCT00706966</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , MRI magnetic resonance spectroscopy imaging , may help learn well dutasteride work patient benign prostatic hypertrophy low-risk prostate cancer . PURPOSE : This clinical trial study MRI magnetic resonance spectroscopy image patient receive dutasteride benign prostatic hypertrophy low-risk prostate cancer .</brief_summary>
	<brief_title>MRI Magnetic Resonance Spectroscopy Imaging Patients Receiving Dutasteride Benign Prostatic Hypertrophy Low-Risk Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether decrease extent prostate cancer measure endorectal MRI magnetic resonance spectroscopy image patient symptomatic benign prostatic hypertrophy low-risk prostate cancer treat dutasteride 6 month . Secondary - To monitor effect dutasteride serum testosterone , dihydrotestosterone , free total prostate-specific antigen ( PSA ) . - To monitor effect dutasteride symptom quality-of-life index . OUTLINE : Patients receive oral dutasteride daily 6 month . Patients undergo endorectal MRI magnetic resonance spectroscopy image baseline 1 , 3 , 6 month . Patients complete quality-of-life questionnaire use International Index Erectile Function Questionnaire , American Urological Association Symptom Index , Functional Alterations due Changes Elimination , Spitzer Quality-of-Life Index baseline 1 , 3 , 6 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm adenocarcinoma prostate Clinical stage T1b , T1c , T2a disease Gleason score ≤ 6 Maximal prostatespecific antigen ( PSA ) &lt; 10 ng/mL Demonstrates intraprostatic metabolite abnormality , consistent adenocarcinoma prostate ( i.e. , ≥ 3 voxels magnetic resonance spectroscopy image [ MRSI ] score 45 ) baseline MRI MRSI Has symptomatic benign prostatic hypertrophy currently undergo watchful wait OR opt undergo permanent seed implant ( i.e. , brachytherapy ) , require neoadjuvant androgen suppression prostate shrinkage No regional lymph node involvement No evidence distant metastasis Zubrod performance status 01 Able swallow retain oral medication Other prior concurrent invasive cancer , localize basal cell squamous cell carcinoma skin Contraindications MRI/MRSI , include follow : Prostate biopsy ( within past 8 week ) continue postbiopsy bleeding Rectal bleed Anal fissure Rectal surgery ( endtoend anastomosis ) Inflammatory bowel disease Prior radical prostatectomy Hip replacement Certain type penile implant Vascular clip Known anaphylactic reaction latex compound Anticoagulant drug Severe claustrophobia Cardiac pacemaker Metal eye Any metallic foreign object body Unstable serious comorbidities include , limited , myocardial infarction , coronary artery syndrome , cardiac arrhythmia , symptomatic congestive heart failure , cerebrovascular accident Major medical psychiatric illness , investigator 's opinion , would preclude completion treatment interfere follow Known hypersensitivity 5αreductase inhibitor drug chemically relate study drug Prior radical surgery ( prostatectomy ) cryosurgery prostate cancer Prior pelvic irradiation , prostate brachytherapy , bilateral orchiectomy Prior concurrent cytotoxic chemotherapy prostate cancer Prior hormonal therapy , luteinizing hormonereleasing hormone agonist ( e.g. , goserelin leuprolide acetate ) , antiandrogens ( e.g. , flutamide bicalutamide ) , estrogens ( e.g. , diethylstilbestrol ) Prior concurrent finasteride , dutasteride , drug know antiandrogenic property ( e.g. , spironolactone progestational agent ) , dietary herbal supplement ( e.g. , selenium , vitamin E , saw palmetto , PCSPES )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>benign prostatic hyperplasia</keyword>
</DOC>